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C57BL/6 (H-2b), but not spontaneous virus-expressing AKR.H-2b congenic, mice generate retrovirus-specific CD8+ CTL responses to the
immunodominant Kb-restricted epitope, KSPWFTTL. AKR.H-2b non-responsiveness is mediated by a peripheral tolerance mechanism. When co-
cultured with primed B6 antiviral pCTL, AKR.H-2b splenocytes are recognized by the antiviral TcR as ‘‘veto’’ cells, which inhibit by an
exquisitely virus-specific, MHC-restricted, veto cell FasL/responder T cell Fas, mediated apoptotic mechanism. Here, AKR.H-2b thymus, lymph
node, and bone marrow cells are also shown to inhibit antiviral CTL generation. Purified AKR.H-2b CD4+ and CD8+ T cells, and B cells, served
effectively as FasL-dependent veto cells. In contrast, AKR.H-2b dendritic cells (DC) did not efficiently veto antiviral CTL responses, despite
expressing sufficient MHC class I/viral peptide complexes for TcR recognition. AKR.H-2b DC also expressed FasL mRNA and cell surface
protein, albeit at a lower level than AKR.H-2b T and B cells. These findings suggest a fail-safe escape mechanism by virus-infected cells for
escape from CTL-mediated immunity.
D 2005 Elsevier Inc. All rights reserved.Keywords: Apoptosis; Tumor immunity; Tolerance/Suppression/Anergy; Dendritic cellsIntroduction
It is generally accepted that antiviral cytolytic T lymphocytes
(CTL) are key immune cells in providing protection against
viral disease. Antiviral CD8+ CTL, by way of their ability to
lyse virus-infected cells and to secrete antiviral cytokines,
including IFN-g, are very effective in defending against viruses,
particularly those transmitted by infected cells and cell:cell
contact. CTL responses may also be of prime importance in
resolving an initial encounter with virus before viral replication
can cause a full blown infection sufficient to elicit high-titer,
high-affinity, neutralizing antibody responses. The require-
ments for generation of antiviral CTL can vary depending on0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.10.009
Abbreviations: Flt3L, human recombinant Flt3 Ligand (typrosine 3 ligand);
GCSA, gross cell surface antigen; MuLV, murine leukemia virus; pCTL,
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E-mail address: william.r.green@dartmouth.edu (W.R. Green).the nature of the virus and other factors. But CD4+ T helper cells
and dendritic cells (DC), as the most efficient antigen presenting
cells for primary CTL responses, are often the most prominent
players in addition to CD8+ pCTL.
To avoid CTL clearance of virus-infected cells, viruses have
developed a number of clever escape strategies (Mahr and
Gooding, 1999; Collins and Baltimore, 1999; Tortorella et al.,
2000; Fruh et al., 1999; Frazer et al., 1999; McMichael and
Phillips, 1997; Green and Smith, 1996). These viral escape
mechanisms fall into three main categories: (1) mutation in
viral amino acid sequences encoding CTL epitopes, (2) viral
genome encoding of proteins that interfere with the production
and presentation of unmutated, normally recognized, viral
epitopes, and (3) induction of suppressive immune cells that
down-modulate the response or enhance viral pathogenesis,
particularly CD4+ T regulatory (Tregs) cells (He et al., 2004;
Dittmer et al., 2004; Beilharz et al., 2004). There is abundant
evidence for variations directly affecting viral epitope presen-
tation, including not only modifications within the epitopes that
inhibit either binding to MHC class I alleles or by the T cell6) 287 – 300
www.e
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processing events. For example, alterations in the amino acid
flanking sequences can cause inefficient processing of the
epitopes from their precursor proteins/larger peptides or their
transport to the ER by TAP 1/2 (Yellen-Shaw and Eisenlohr,
1997; Yellen-Shaw et al., 1997; Del Val et al., 1991; Eisenlohr
et al., 1992; Ossendorp et al., 1996; Eggers et al., 1995;
Bergmann et al., 1994; Bergmann et al., 1996; Couillin et al.,
1994; Neisig et al., 1995). Viral immune escape through amino
acid variation within or adjacent to the CTL epitope requires
that the amino acid sequence of this region not be critical to
viral protein function, such that the alteration can be tolerated
by the virus. Alternatively, for viral proteins that inhibit epitope
processing or presentation, virtually every step of the endog-
enous class I pathway may represent a target of opportunity for
a virus counter measure leading to escape from antiviral T cells.
In fact, a variety of viral proteins encoded especially by the
large-genome DNA viruses, such as the Herpes family, have
been described that interfere with several stages of the class I
presentation pathway (reviewed in Hengel et al., 1999). In
contrast, however, most retroviruses have relatively small
genomes, particularly the simple murine leukemia viruses
(MuLV). There are only three genes – gag, pol, and env –
encoding highly conserved polyproteins which collectively
perform all of the functions necessary for viral replication,
spread, and pathogenesis.
Another level of control of the induction of CD8+ CTL lytic
and/or IFN-g producing responses to some viruses, including,
most relevant to the discussion here, retroviruses such as Friend
MuLV, appears to be mediated by CD25+ CD4+ T regulatory
cells (He et al.) and (Dittmer et al.). Whether the regulatory
CD4+ T cells involved are pre-existing ‘‘natural’’ Tregs, or
induced by the viral infection, their mechanism(s) of down-
modulation varies from system to system and is often
incompletely understood. In addition, in a recent publication
on the LP-BM5 MuLV isolate, that causes murine AIDS,
evidence was provided suggesting that Tregs were necessary
for the full pathogenic effect induced by the virus, which was
presumably mediated, at least in part, by other immune cells
(Beilharz et al.). As this viral disease involves a profound
immunosuppression affecting all T cell (and B cell) responses
studied, including CTL generation, this syndrome provides an
example of an indirect mechanism by which Treg cells promote
retroviral escape from CD8+ T cell immunity.
We (White et al., 1994; Coppola and Green, 1994) and others
(Sijts et al., 1994) have previously reported that C57BL/6 (B6,
H-2b) mice generate type-specific CTL responses to an
immunodominant Kb restricted epitope, KSPWFTTL located
in the membrane spanning domain of p15E/TM of AKR/Gross
MuLV. AKR.H-2b congenic mice, though carrying the responder
H-2b haplotype, spontaneously express endogenous MuLV and
are low/non-responders for AKR/Gross MuLV-specific CTL
(Green, 1984; Wegmann et al., 1988). However, this lack of
responsiveness is apparently not due to central tolerance via
thymic deletion. Rather, essentially normal antiviral pCTL
frequencies are observed (Wegmann et al., 1992). Specific
antiviral CTL non-responsiveness is due instead to modulatoryAKR.H-2b lymphoid cells, which inhibit CTL generation both in
vivo (Rich andGreen, 1995) and in vitro (Rich andGreen, 1996).
Thus, despite their expression of endogenous retroviral antigens
and Kb (Green, 1983) untreated viable AKR.H-2b spleen cells
cause dramatic inhibition of the B6 antiviral CTL response to in
vitro restimulation with AKR/Gross MuLV-induced tumor cells
(Rich and Green, 1996) or alternatively, with soluble
KSPWFTTL peptide (unpublished results). This inhibition is
(1) specific, as AKR.H-2b modulator spleen cells do not inhibit
allogeneic MHC-specific CTL production, (2) MHC restricted,
(3) dependent on direct contact of AKR.H-2b cells in a dose-
dependentmanner with the responder cell population, and (4) not
due to soluble factors. To control for the possibility that AKR.H-
2b cells inhibited B6 antiviral responsiveness as a consequence of
minor H specific allo-reactive responses mediated by the
AKR.H-2b cells, spleen cells from young, genetic background
matched AKR.H-2b:Fv-1b double congenic mice (that are very
low expressers of endogenous retroviral antigens and antiviral
CTL responders (Green, 1986), (Green, 1987)) were employed
in parallel in MLTC cultures (Rich and Green, 1996). Unlike the
strong inhibition of the B6 antiviral CTL response by AKR.H-2b
cells, addition of spleen cells from the AKR.H-2b:Fv-1b strain
leads to very inefficient, if any, specific inhibition. This finding
argued against allo-reactive ‘‘back recognition’’ as the mecha-
nism of inhibition of antiviral CTL generation.
The mechanism of inhibition of the antiviral CTL response
was shown to be apoptosis of antiviral CD4+ and/or CD8+ T
cells via Fas/Fas ligand (FasL) interactions (Rich and Green,
1999). Thus, whereas B6.gld (FasL) responders were as
sensitive to inhibition by AKR.H-2b modulator cells as B6,
B6.lpr (Fas) responders were largely insensitive to inhibition,
indicating that the responder cells needed to express Fas. Other
functional experiments indicated that the inhibitory AKR.H-2b
cells must express FasL. These results collectively implicated a
veto cell (reviewed in Fink et al., 1988) mediated, activation-
induced cell death (AICD) type of mechanism: viral antigen-
positive AKR.H-2b cells expressing FasL induce apoptosis of
the antiviral T cells (‘‘veto’’ them) when the AKR.H-2b cells
are specifically recognized by responder T cells via their TcR.
Indeed, veto cell-mediated apoptosis was directly shown by
annexin V analysis of Kb/KSPWFTTL-tetramer-positive, anti-
gen-specific antiviral CTL via multi-parameter flow cytometry
and by the subsequent depletion of Kb/KSPWFTTL tetramer-
specific CTL (Rich and Green, 2000, 2002). Consistent with
these results, the CTL response in the presence of inhibitory
cells could be restored by several cytokines/agents that have
been shown to interfere with FasL/Fas induced cell death [e.g.,
IL-2, IL-15, transforming growth factor h (TGF-h), lipopoly-
saccharide, 9-cis-retinoic acid] but not others, such as TNF-a
(Rich and Green, 1999).
Here, we further define this type of viral escape mechanism
by examining various AKR.H-2b tissues and spleen cell
subpopulations for such specific veto activity. We demonstrate
that naı¨ve AKR.H-2b CD4 and CD8-positive T cells, and B
cells, each can serve effectively to specifically down modulate
the AKR/Gross MuLV-specific CTL response. For each of
these cell subpopulations, the mechanism involved their FasL-
Fig. 1. Inhibition by AKR.H-2b spleen cells is exquisitely specific. B.GV-
primed B6 responder spleen cells were restimulated with B.GV irradiated tumor
cells with or without viable unfractionated AKR.H-2b splenocytes, as shown.
AKR/Gross virus-, or BALB.B minor H, -specific CTL lysis was assayed by
testing against either syngeneic (to B6) ESG2 or BALB.B.1k (AKR/Gross
viral antigen negative) target cells, respectively, as shown. E:T ratios shown
were as follows: Black, 200:1; dark gray, 40:1; light gray, 8:1, or white1.6:1.
This result was repeated in a second experiment.
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despite expression of viral Ags and both MHC class I and class
II, were strikingly ineffective in inhibiting antiviral CTL
generation. Whether the inability of such DC to serve as veto
cells reflects a reduced expression of FasL or is due to other
DC properties is discussed in the context of this physiological
virus escape mechanism.
Results
Inhibition by AKR.H-2b spleen cells is specific for AKR/Gross
MuLV-specific CTL responsiveness
To confirm that the inhibitory effect of viable AKR.H-2b
splenocytes was specific for AKR/Gross MuLV-specific CTL
responsiveness, CTL of other specificities were examined.
Allo-MHC-specific CTL responses were previously shown to
be insusceptible to AKR.H-2b vetoing (Rich and Green, 1996),
but these are very strong responses that can occur after primary
stimulation. Here, we sought to compare AKR.H-2b veto
susceptibility of antiviral CTL generation to another MHC-
restricted CTL response, but of irrelevant specificity. Thus, a
minor-H-specific CTL response was assessed in parallel. Mice
primed with B.GV (BALB.B derived) and restimulated with
this same background mis-matched, viral antigen-positive
tumor cell line, generated strong AKR/Gross MuLV (ESG2
target), as well as minor-H (AKR/Gross virus-negative
BALB.B.1K target), -specific CTL responses within the same
MLTC well (Fig. 1). When AKR.H-2b splenocytes were
included in these restimulation wells, only the viral, not the
minor-H, -specific CTL response was inhibited. These data
provided a very strong argument for the exquisite specificity of
AKR.H-2b veto cell inhibition, particularly given that the
antiviral and anti-minor H CTL were generated concurrently in
response to a common (B.GV tumor cell) restimulating APC.
AKR/Gross MuLV-specific B6 CTL generation is inhibited by
cells from AKR.H-2b spleen, thymus, lymph nodes, and bone
marrow
As we have previously published (Rich and Green, 1999,
2000, 2002), viral Ag+/FasL+ unfractionated AKR.H-2b sple-
nocytes specifically inhibit, i.e., veto, B6 AKR/Gross MuLV-
specific CTL responses. To test whether other lymphoid organs
from AKR.H-2b mice could similarly serve as a source of such
‘‘veto’’ cells, AKR.H-2b lymph node, bone marrow, thymus, or
spleen (as a positive control for inhibition), cells were included
in MLTC CTL restimulation cultures (Fig. 2, top). AKR.H-2b
lymph node and bone marrow cells inhibited virus-specific CTL
at levels roughly comparable to those mediated by AKR.H-2b
splenocytes. Compared to the striking inhibition by AKR.H-2b
spleen, lymph node, and bone marrow cells, thymocytes
mediated only a moderate decrease in antiviral CTL production,
and this partial inhibition was age-dependent (see below). In
contrast, inclusion of viral antigen-negative cells from B6
spleen, lymph node, bone marrow, or thymus into MLTC wells
did not diminish the antiviral CTL response (Fig. 2, bottom).This control series argued against steric hindrance and other
possible artifacts as an explanation for CTL inhibition mediated
by cells from the AKR.H-2b tissues.
We have previously shown that the viral Ag positivity of
AKR.H-2b thymocytes, as measured both serologically and by
the ability of irradiated thymocytes to restimulate B6 antiviral
CTL responses, increases relatively slowly over time (Green,
1987). These kinetics roughly parallel the well-known increase
in the thymic expression of endogenous AKR/Gross MuLV in
which virus expression in the thymus follows that in the spleen
and is a primary reason for the delay in the appearance of
spontaneous thymomas in AKRmice. Here, we demonstrate that
these delayed kinetics of viral Ag expression correlate with the
capacity of AKR.H-2b thymocytes to mediate veto cell function
(Fig. 3). Whereas thymocytes from pooled 10- to 13-week-old
AKR.H-2bmice could inhibit the antiviral CTL response by only
about 47%, thymocytes from pooled 34-week-old mice medi-
ated a 78% decrease in B6 antiviral CTL generation. In contrast,
AKR.H-2b spleen cells express high levels of AKR/Gross
MuLV-associated CTL epitopes from as early as 4 weeks of
age (Green, 1983) and are capable of efficient veto cell inhibition
even when procured from young, here 10- to 13-week-old, mice
(Fig. 3). As a control, all B6 tissues (Fig. 2, bottom) failed to
exhibit veto activity, consistent with B6 mice displaying an
AKR/Gross MuLV-negative status (Green, 1983).
The observed inhibition by cells from AKR.H-2b spleen,
lymph node, and thymocytes was specific: B6 antiviral CTL
generation, but not the induction of primary in vitro allogeneic
B6 anti-H-2d specific-CTL against P815 (H-2d) target cells, was
inhibited by the inclusion of AKR.H-2b cells into parallel MLTC
(data not shown). As indicated above, AKR.H-2b bone marrow
Fig. 3. The capacity of AKR.H-2b thymocytes to mediate veto cell function
correlates with increased viral Ag expression upon aging. B.GV-primed B6
responder cells were stimulated with ESG2 tumor cells. Splenocytes and
thymocytes were prepared from AKR.H-2b mice and added to MLTC wells as
shown. Effector cells were harvested and assayed in a 51Cr release assay fo
AKR/Gross virus-specific CTL lysis of ESG2 tumor target cells. Shown is an
E:T of 50:1. Similar results were observed at E:Ts of 10:1 and 2:1. The age
related increased capacity of AKR.H-2b thymocytes to serve effectively as veto
cells was repeated in a second experiment.
Fig. 2. AKR/Gross MuLV-specific B6 CTL generation is inhibited by cells from
multiple AKR.H-2b murine organs. SL1-primed B6 responder spleen cells were
restimulated with ESG2 irradiated tumor cells. Tissues from AKR.H-2b (or from
control B6) mice were processed, and where shown, 2  106 cells were added to
MLTC wells. Tissues were harvested from pooled 14-week-old AKR.H-2b mice.
Effector cellswere harvested and tested in a 51Cr release assay forAKR/Gross virus-
specific CTL lysis of ESG2 tumor target cells. Shown is an E:T of 100:1. Similar
results were observed at E:Ts of 20:1 and 4:1. Each AKR.H-2b tissue type was
tested for inhibitory capacity in at least two experiments, the result being the same.
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cells – inhibited antiviral CTL responses (Fig. 2). This inhibition
was mediated via FasL/Fas interactions (see below). However,
unlike AKR.H-2b veto cells from the other tissues, AKR.H-2b
bone marrow cells also inhibited B6 allogeneic H-2d-specific
CTL generation (data not shown). The mechanism(s) by which
AKR.H-2b bone marrow cells inhibit allogeneic CTL respon-
siveness may be complex and is yet to be fully determined.
AKR.H-2b splenic CD4 and CD8-positive T lymphocytes and B
lymphocytes inhibit B6 antiviral CTL generation via FasL/Fas
interactions
We previously demonstrated that unfractionated AKR.H-2b
splenocytes specifically inhibited antiviral CTL responsivenessvia FasL/Fas interactions between FasL+AKR.H-2b splenic veto
cells and Fas+ B6 antiviral T cells. The crucial observation was
the dependence of veto cell inhibition on responder cell Fas
expression as determined by comparison of B6 versus B6.lpr
(Fas/) responder mice. As also previously shown, both
AKR.H-2b CD4+ and CD8+ T lymphocytes, as well as B lym-
phocytes, could each dramatically and specifically inhibit the
stimulation of B6 AKR/Gross virus-specific CTL responses
both in vivo (Rich and Green, 1995) and in vitro (Rich and
Green, 1996). However, the mechanism(s) of inhibition was not
defined. To test which of these splenic lymphocyte subpopula-
tions were specifically inhibiting B6 antiviral CTL responsive-
ness via a FasL/Fas mechanism, highly purified AKR.H-2b
splenic subset cells were co-cultured in MLTC wells with either
B6 or B6.lpr primed responder lymphocytes and tumor stimu-
lator cells (Fig. 4). In keepingwith our previous results (Rich and
Green, 1996), highly purified AKR.H-2b CD4+ as well as CD8+
T lymphocytes specifically inhibited B6 AKR/Gross MuLV-
specific CTL responses (Fig. 4, top left). The relative efficiency
of inhibition mediated by these AKR.H-2b T cell subsets varied
in magnitude somewhat from experiment to experiment but was
always substantial and overall suggested a similar inhibitory
capacity. However, when AKR.H-2b CD4+ or CD8+ T lympho-
cytes were co-cultured with B6.lpr responder lymphocytes (Fig.
4, bottom left), there was no diminution of the antiviral CTL
response, consistent with FasL/Fas apoptosis as the mechanism
of inhibition. The representative experiment shown was one of a
total of 3 experiments with a similar pattern of results.r
-
Fig. 4. AKR.H-2b splenic T lymphocytes and B lymphocytes inhibit B6 antiviral CTL generation via FasL/Fas interactions. B6 versus B6.lpr mice were primed with
B.GV tumor cells. MLTC cultures were set up with irradiated tumor stimulator cells and with or without purified AKR.H-2b CD4+ or CD8+ or B lymphocyte splenic
veto cells, as indicated. Effector cells were harvested and assayed in a 51Cr release assay for AKR/Gross virus-specific CTL lysis of ESG2 tumor target cells.
R.F. Rich et al. / Virology 346 (2006) 287–300 291To test whether AKR.H-2b B lymphocytes could, like their T
cell counterparts, inhibit B6 antiviral CTL responsiveness via a
FasL/Fas mechanism, highly purified (95–99%) AKR.H-2b B
lymphocytes were included in MLTC cultures as above. Again,
there was clear inhibition of AKR/Gross MuLV-specific CTL
lysis when primed B6 mice were the source of the antiviral
CTL (experiment 2 top right). In sharp contrast, there was, if
anything, a slight increase in the generation of virus-specific
CTL when B6.lpr (Fas/) responder cells were utilized in the
specific experiment shown (experiment 2, bottom right),although this elevation was only a sporadic result. The finding
that AKR.H-2b B lymphocytes inhibited the generation of B6,
but not B6.lpr, responder antiviral CTL was observed in a total
of 6 of 7 experiments.
AKR.H-2b veto cell subset-mediated apoptosis of
Kb/KSPWFTTL tetramer+ CTL
In order to visualize the depletion of KSPWFTTL-specific
CTL by the various AKR.H-2b veto cell types, Kb/KSPWFTTL
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vitro restimulation cultures when CTL activity was measured.
Following restimulation with viral Ag+ ESG2 tumor cells in the
absence of veto cells, there was substantial specific staining of
CD8+ Tcells by the Kb/KSPWFTTL tetramer and corresponding
robust lytic activity, indicating that about 27% of the CD8 pop-
ulation represented epitope-specific CTL (Supplemental Fig. 1).
Such significant staining above background was not observed
with an irrelevant negative control labeled Kb/SSWDYITV
tetramer (not shown). In sharp contrast, when unfractionated
AKR.H-2b, or AKR.H-2b B subset (Supplemental Fig. 1), veto
cells were included in the restimulation cultures, there was an
essentially complete depletion to 0.4% Kb/KSPWFTTL
tetramer+ CTL and a corresponding drastic inhibition of the
generation of lytic CTL. Thus, the visual depletion of
KSPWFTTL-specific CTL mediated by each AKR.H-2b veto
cell subset, coupled with the uniform lack of CTL inhibition
when B6.lpr mice were employed as responders (Fig. 4), clearly
implicates FasL/Fas apoptosis as the mechanism of inhibition,
regardless of the lymphoid subset identity of the veto cell.
Flt3L-generated AKR.H-2b DC do not serve as efficient veto
cells
To test whether AKR.H-2b splenic DC could also serve as a
source of veto cells, highly purified splenic DC from Flt3L-
treated mice were added into B6 antiviral restimulation cultures,
as above (Fig. 5). In a total of 6 of 8 experiments, co-culture withFig. 5. Flt3L-generated AKR.H-2b DC do not serve as efficient veto cells.
B.GV-primed B6 responder lymphocytes were cultured with or without
irradiated tumor stimulator cells, with or without purified AKR.H-2b splenic
DC, as indicated. Additionally, AKR.H-2b unfractionated spleen cells versus
purified DC were utilized as APC (in the absence of tumor cells), without or
with gamma irradiation treatment, as indicated. Shown is an E:T of 10:1.
Similar results were observed at E:Ts of 50:1 and 2:1.AKR.H-2b DC did not efficiently inhibit the restimulation of B6
responder lymphocytes provided by ESG2 tumor stimulator
cells (i.e., inhibition of 0–24% at a given E:T ratio, representing
a 0- to 1.5-fold decrease considering the E:T titration, of CTL
activity). Importantly, in all 8 experiments performed, the Flt3L
treatment derived unfractionated population of splenocytes, and
in those experiments where tested, selected lymphoid cell veto
subpopulations (as in Fig. 4), inhibited the antiviral CTL
response by 20- to 25-fold. These data served as an internal
control and demonstrated that the Flt3L treatment itself did not
measurably interfere with the ability of the splenic T and B cells
to serve as veto cells. Of note, in one of the two experiments in
which FLt3L-induced AKR.H-2b DC demonstrated some
inhibition of the antiviral CTL response, the purity of the DC
was the least of any of these experiments, at 93%. This raised the
possibility that contaminating AKR.H-2b CD4+ T, CD8+ T, and/
or B, veto cells, each of which inhibited the antiviral CTL
response by >25-fold in this experiment, may have contributed
to the observed ‘‘DC’’ inhibition. In the other experiment where
DCs were scored as being inhibitory, they were 97% pure, and
there was actually only moderate inhibition (47% or 17%
inhibition at E:Ts of 20:1 and 4:1, respectively) of antiviral CTL
generation.
As we have previously shown (Rich and Green, 1996,
1999), unirradiated/viable unfractionated, AKR.H-2b spleen
cells restimulate antiviral CTL generation poorly relative to the
same cells used as irradiated stimulators (Fig. 5). In contrast,
unirradiated AKR.H-2b DC could serve efficiently as a sole
source of spontaneous viral Ag presenting APC for the
generation of B6 antiviral CTL (Fig. 5). Indeed, the level of
antiviral CTL lysis following restimulation with AKR.H-2b DC
(whether the DC were viable or irradiated) was comparable to
the stimulation provided by irradiated ESG2 tumor stimulator
cells. The ability of AKR.H-2b DC to stimulate antiviral CTL,
even under conditions (i.e., non-irradiation) allowing veto cell
activity to be revealed, was entirely consistent with their
efficiency in presenting AKR/Gross MuLVAg to B6 respond-
ing T lymphocytes and their inefficiency as functional veto
cells.
‘‘Normal’’ AKR.H-2b DC are also inefficient veto cells
It seemed possible that the relative inability of the AKR.H-
2b DC to veto efficiently was somehow due to the use of Flt3L
treatment. To test whether non-Flt3L generated, ‘‘normal’’ DC,
had similar functional capabilities, splenic DC from untreated
AKR.H-2b mice were also purified (see Materials and methods
for details). Similar to the data obtained for AKR.H-2b DC
obtained through Flt3L treatment, such uninduced AKR.H-2b
DC were consistently able to efficiently present endogenous
retroviral antigen at the in vitro restimulation phase in the
generation of antiviral CTL, with the levels of lysis generated
again roughly comparable to the lysis by CTL generated
through ESG2 tumor cell restimulation (Fig. 6). Also similar
to Flt3L-induced DC, these normal AKR.H-2b DC did not
serve as efficient veto cells (Fig. 6). Rather, in 8/8 total
experiments (as in Fig. 6), the added DC appeared to further
Fig. 6. ‘‘Normal’’ AKR.H-2b DC are inefficient veto cells. B.GV-primed B6
responder lymphocytes were restimulated with ESG2, with or without viable
unfractionated AKR.H-2b splenocytes or collagenase-derived normal DC (see
Materials and methods), as shown, or with AKR.H-2b DC alone. Effector cells
were harvested and tested in a 51Cr release assay for AKR/Gross virus specific
CTL lysis, as shown. E:T ratios shown were as follows: Black, 200:1; white,
40:1. The data shown are representative of 7 additional experiments.
Fig. 7. FasL message expression by AKR.H-2b splenic cell populations. Real-
time qRT-PCR was used to determine levels of FasL mRNA in unfractionated
spleen, purified CD4+ and CD8+ T cells, B cells, and DC from AKR.H-2b mice.
Plotted are averaged FasL relative expression values for mRNA (normalized to
h-actin) from two real-time PCR determinations per sample. The purity of naı¨ve
AKR.H-2b CD4+ and CD8+ T and B lymphocytes (panel A) was 95%. The
corresponding functional 51Cr release assay data demonstrated >25-fold specific
inhibition of AKR/Gross MuLV-specific CTL responses when each of these
lymphocyte subset cells was added to MLTC restimulation cultures at day 1 (not
shown). In panel B, the purity of both Flt3L treatment-derived AKR.H-2b B
lymphocytes as well as DC (B) was 99%. Whereas AKR.H-2b B lymphocytes
inhibited the generation of AKR/Gross virus-specific CTL by ¨5-fold, there
was little, if any, effect on CTL generation upon addition of purified DC (not
shown). Mouse serum albumin (MSA) was used as a control protein.
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tumor cells and thereby actually increase, not inhibit, the
antiviral CTL response. These data collectively demonstrate
the functional equivalence of Flt3L treatment-derived versus
normal AKR.H-2b DC and argue that their inability to serve as
a source of efficient veto cells is independent of the method of
preparation.
FasL expression by AKR.H-2b splenic cell populations
Because veto activity in this system is mediated by veto cell
FasL, it was important to determine whether AKR.H-2b cells
expressed message for FasL and how this correlated with veto
activity. Thus, real-time PCR quantification of mRNA was
performed on purified splenic lymphocyte subsets (Fig. 7A).
Because reports of FasL expression by B-lineage cells are
somewhat limited (Hahne et al., 1996; Samuelsson et al., 1997;
Tanner and Alfieri, 1999; Sasaki et al., 2000; Silvestris et al.,
2001), it was of particular interest to compare expressed FasL
RNA levels of AKR.H-2b B, versus T, splenic lymphocyte
subset cells. As determined by qRT-PCR, FasL mRNA
expression was readily detectable for both AKR.H-2b B and
the T cell subpopulations (Fig. 7A). Although perhaps 2-fold
differences were observed between certain cell types in
particular comparisons such as in the experiment of Fig. 7A,
these differences were not consistent considering the six total
experiments performed. Highly enriched (93–99% pure)
AKR.H-2b splenic DC (from the experiments summarized inFig. 5 that showed little/no DC veto activity) were also assayed
for FasL message expression. Similar to the lymphocyte
subpopulations, FasL mRNA was easily detectable in DC,
generally approaching 2- to 3-fold less then lymphoid subset
expression (Fig. 7B). Over the course of six experiments, the
FasL mRNA expression by DC averaged ¨50% lower than
FasL message of AKR.H-2b B and T lymphocytes. Conversely,
in the second of the two experiments where the AKR.H-2b DC
were scored as being slightly inhibitory (see text discussion to
Fig. 5, above), their relative expression of FasL message was as
high as their T and B lymphocyte counterpart cells and
underscored the possibility that DC may have the potential to
serve as veto cells if the FasL expression reaches a threshold
value.
Because intracellular FasL message does not necessarily
correlate with expression of FasL protein, flow cytometric
analyses were performed to determine cell surface FasL
expression on AKR.H-2b splenocyte subsets. Highly purified
(93%), non-induced DC preparations were compared with
unfractionated AKR.H-2b spleen cells, containing CD4+ and
CD8+ T cells and B cells, that efficiently vetoed the response
(Fig. 8). AKR.H-2b subsets were identified and stained for
FasL by withdrawing samples at day 3 of culture with primed
Fig. 8. Cell surface FasL expression by AKR.H-2b splenic cell populations. Three days following the initiation of the MLTC, a representative sample of cells
containing AKR.H-2b CD4+ and CD8+ lymphocytes (following the addition of unfractionated AKR.H-2b spleen cells), or normal (see legend to Fig. 6) AKR.H-2b
DC, were stained for cell surface FasL expression (panels A–C, E–G). AKR.H-2b CD4 and CD8a-positive T lymphocytes were distinguishable from B6 responder
cells by virtue of their varied (Thy1.1+) allelism. Viable cells were gated based on their forward and side scatter profiles. The M1 region defining the percent of cells
staining positively was set up so that isotype control mAb stained 5% of the cells. Purple tracings represent staining of AKR.H-2b cells with mAb to FasL; green,
isotype control mAb staining. At day 6 of cultures, remaining B6 responder lymphocytes, having been cultured with or without unfractionated AKR.H-2b
splenocytes or AKR.H-2b DC, were assayed for AKR/Gross MuLV-specific CTL lysis (panels D and H). Shown is an E:T of 20:1. Similar results were observed at
E:T of 100:1.
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subsequently assessed for CTL generation at day 6 of culture
(panels D, H). Our previous kinetic experiments indicated that
it was at days 3–4 of culture at which veto cell-mediated, FasL/
Fas-dependent killing was maximal (Rich and Green, 2002).
Of all staining experiments performed, some variability in
FasL expression was observed, as represented by experiments 1
and 2 of Fig. 8. A substantial (17%–42%) subset of CD4+
(panels A, E) and CD8+ (panels B, F) AKR.H-2b T cells
displayed cell surface FasL over background isotype control
values. In contrast, FasL expression by AKR.H-2b DC was
either essentially undetectable (0%, panel C) or very minimal
(8%, panel G), and seemed to correlate with partial veto activity
(panels D, H): i.e., undetectable veto activity and FasL
expression in experiment 1 versus some but minimal veto
activity and FasL expression in experiment 2. However, it
should be noted that the DC purity was 99% in experiment 1
versus 93% in experiment 2. Thus, we cannot exclude the
possibility that the presence of contaminating AKR.H-2b CD4+
and CD8+ T lymphocytes, and/or B cells, might have been partly
or fully responsible for the observed FasL expression and the
partial inhibition of CTL generation in experiment 2, particularly
given the very strong veto activity observed for unfractionated
spleen cells. Along these lines, veto-efficient AKR.H-2b B cells
are also present in the unfractionated AKR.H-2b spleen cell
addition, and it was of interest to also determine their levels ofcell surface FasL expression. Because no marker such as Thy1
was available to distinguish the AKR.H-2b, versus the responder
B6, B cells, the latter were depleted prior to the initiation of the
MLTC restimulation cultures (see Materials and methods). By
this approach and staining with anti-CD19 and anti-Flt3L mAbs,
AKR.H-2b B cells also appeared to express FasL at levels similar
to their CD4+ and CD8+ veto cell counterparts (not shown).
Taken together, these results are in keeping with the FasLmRNA
expression studies and demonstrate at least less cell surface FasL
expression by veto-inefficient AKR.H-2b DC preparations
versus efficient splenic lymphoid veto subsets. These findings
thus suggest the possibility that a relative deficiency in FasL
expression byAKR.H-2b DCmay be the basis for their poor veto
activity.
Expression of CD80/86 costimulatory molecules by DC,
serving as APC in antiviral CTL generation, does not play a
role in T cell susceptibility to inhibition by AKR.H-2b veto cells
We also considered the possibility that AKR.H-2b DC
exhibited poor veto activity due to factors other that their lower
(induced) expression of FasL mRNA and cell surface FasL.
Specifically, rather than insufficient display of FasL or other
veto-associated molecules by DC, it seemed possible that
AKR.H-2b DC, when tested as veto cells in the CTL
restimulation cultures, actually functioned as the dominant
Fig. 10. AKR.H-2b splenic DC subsets do not inhibit AKR/Gross MuLV-
specific CTL lysis. B.GV-primed B6 responder spleen cells were restimulated
with KSPWFTTL peptide without or with either unfractionated splenic cells or
purified total DC, myeloid DC, lymphoid DC, or plasmacytoid DC, from Flt3L
treated AKR. H-2b mice, as shown. Effector cells were harvested and tested in a
51Cr release assay for AKR/Gross MuLV-specific CTL lysis of ESG2 target
cells. E:T ratios shown were as follows: Black, 100:1; dark gray, 20:1; light
gray, 4:1.
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CTL. Compared to standard restimulation by tumor cell or
soluble peptide, these DC-induced antiviral T cells might be
resistant to veto attack, thus masking an inherent ability of
AKR.H-2b DC to veto. We questioned whether responder T cell
insusceptibility to AKR.H-2b DC veto cells might depend on T
cell receipt of signal 2/costimulation via CD80/86, along with
peptide/MHC activation, by DC APC.
To test this possibility, DC from wild type versus B6.CD80/
86 knockout (KO) mice were compared as APC. Immunodo-
minant peptide 12 (KSPWFTTL)-pulsed CD80/86 KO DC,
when used as the sole source of Ag in in vitro restimulation
cultures, induced a somewhat diminished response compared
to CTL restimulated by peptide 12-pulsed normal B6 DC (Fig.
9). This finding was consistent with the likelihood that classic
co-stimulation of CD28+ T cells (CD8+ and/or CD4+) via
CD80/86 on APC is required for optimal antiviral CTL
generation. However, whether the peptide-pulsed DC were of
wild type B6 or of B6.CD80/86 KO origin, there was clear and
similar inhibition of CTL responsiveness by unfractionated
splenic AKR.H-2b veto cells (Fig. 9). In two repeat experi-
ments, although the magnitude of the CTL response and the
amount of veto inhibition varied from experiment to experi-
ment, there was no evidence for a consistent differential
susceptibility to veto inhibition between CTL responses raised
in the presence versus absence of APC CD80/CD86 triggered
co-stimulation.
Veto cell activity of DC subpopulations
Along the same lines of the potent stimulatory capacity of
AKR.H-2b DC expressing endogenously derived viral peptide/
MHC class I complexes, it seemed possible that certain DCFig. 9. Expression of CD80/86 costimulatory molecules by DC does not play a
role in T cell susceptibility to inhibition by AKR.H-2b veto cells. Highly
enriched (95%) DC, originating from B6 versus B6.CD80/86KO mice, were
used at 1  106/well as a source of restimulation by pulsing with synthetic
KSPWFTTL peptide, with or without inclusion of AKR.H-2b veto cells, as
shown. As ultimate positive controls, the tumor cell restimulated response and
its susceptibility to vetoing was of a pattern similar to that shown above and
was thus omitted for the sake of brevity. E:T ratios shown were as follows:
Black, 200:1; dark gray, 100:1; light gray, 20:1.might be highly stimulatory, and thus in the context of an
unfractionated DC population, might mask the functional
ability of another DC subpopulation to veto antiviral CTL
generation. To address this possibility, our approach was to test
the isolated major subpopulations of splenic DC for their
inherent veto capability. In order to determine whether AKR.H-
2b myeloid, lymphoid, and plasmacytoid DC varied in their
ability to serve as veto cells, fractionation of purified total DC
into these DC subsets was performed through flow cytometric
cell sorting (Fig. 10) (see Materials and methods for details).
Whereas unfractionated Flt3L derived AKR.H-2b spleen cells,
containing veto-capable T and B lymphocytes, inhibited AKR/
Gross MuLV-specific lysis by approximately 5-fold (based on
comparison of E/T ratios yielding similar levels of lysis), there
was no evidence that any of the three purified DC subsets
caused significant inhibition of the virus-specific CTL response
(Fig. 10). Thus, like the total AKR.H-2b DC population, cells
from all three AKR.H-2b DC subsets failed to serve as veto
cells. Indeed, the inclusion of AKR.H-2b DC into the CTL
restimulation cultures often caused, if anything, a further
stimulation of antiviral CTL production. This pattern of results
was replicated in two additional experiments for myeloid and
lymphoid DC. For plasmacytoid DC, the limitation was the cell
numbers available to test. However, with the caveat of the
somewhat suboptimal cell numbers which were available for
testing, in a repeat experiment, there was no evidence for
inhibition by plasmacytoid DC.
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In summary, AKR.H-2b splenic CD4+ and CD8+ T cells, as
well as B cells, are each able to specifically veto the generation
of AKR/Gross MuLV-specific CTL. These lymphocyte sub-
populations are viral Ag+ and express appreciable levels of
FasL message. Indeed, the use of B6.lpr (Fas/) responder
mice as a source of antiviral pCTL/CTL (Rich and Green,
1999), and a class I MHC tetramer presenting the immunodo-
minant viral epitope to follow pCTL/CTL deletion (Rich and
Green, 2000, 2002), allowed us to demonstrate that the veto
mechanism consists primarily, if not exclusively, of veto cell
FasL-mediated apoptosis of Fas+ responder T cells (Fig. 4,
Supplemental Fig. 1). In addition to AKR.H-2b CD4+ and
CD8+ T veto cells, this was also the case for AKR.H-2b B cell
veto action, interesting in light of the less frequently published
observations of FasL expression by B-lineage cells (see above).
Of note, the class II MHC+ nature of B cells allows them to
present class II-associated CD4+ T cell epitopes to veto
antiviral CD4 T cells, as well as class I-restricted antiviral
CD8+ pCTL/CTL. Thus, the existence of functional, FasL-
dependent AKR.H-2b B veto cells would explain our previous
observations that antiviral CD4+ Th responder cells are also the
target of unfractionated AKR.H-2b veto cells, and that
inhibition of such Th cells is sufficient to abrogate the CTL
response (Rich and Green, 1999).
In sharp contrast, normal or FLT3L-induced AKR.H-2b DC,
although MHC class I- and class II-positive and viral Ag+, and
thus capable of targeting both CD8+ pCTL/CTL and CD4+ Th,
do not serve effectively as veto cells (Fig. 5). Interestingly,
AKR.H-2b DC express somewhat lower levels of message for
FasL (Fig. 7) and cell surface FasL (Fig. 8), when compared to
their T and B cell counterparts. This raises the possibility that a
threshold value of FasL expression may be necessary to trigger
responder T-cell-expressed Fas signaling and thus begin the
death cascade leading to apoptosis of antiviral CTL and/or Th.
Alternatively, the FasL expression by DC may exceed such
a putative required threshold such that other DC properties are
the basis for their inability to veto. Such properties might
include limiting levels of other cell surface molecules that are
required for veto cell action. However, the ability of AKR.H-2b
DC to very efficiently stimulate antiviral CTL responses, when
used as either irradiated or viable stimulator cells, argues
against any such deficiency that would relate to T cell:veto/
APC cell adhesion, TcR recognition and engagement, etc.
On the other hand, the lack of veto function by AKR.H-2b
DC may reflect not what these DC fail to express at sufficient
levels, but rather what they uniquely express, relative to the
AKR.H-2b lymphoid subsets that veto. For example, DC
express relatively high levels of CD80 and CD86 and thus
through ligation of responder T cell CD28 provide signal 2/co-
stimulation as well as TcR-mediated signal 1. Because co-
stimulation can provide anti-apoptotic signals, in part by
upregulation of Bcl-2 and Bcl-xL (Noel et al., 1996; Radvanyi
et al., 1996), AKR.H-2b DC may confer resistance to FasL-
induced apoptosis to the antiviral CD8+ pCTL/CTL and CD4+
Th cells. Thus, AKR.H-2b DC may actually have intrinsic vetocell function, but this may be masked by their ability to provide
co-stimulatory signals, unlike AKR.H-2b lymphoid cells that
are functional veto effectors. Perhaps similarly, we have been
unable to demonstrate veto cell activity for normal AKR.H-2b
macrophages (Rich and Green, 1996). These macrophages, like
AKR.H-2b DC, are viral antigen and MHC class II+ and
capable of providing co-stimulation and indeed readily
stimulate an AKR/Gross MuLV-specific CTL response (Rich
and Green, unpublished). However, we determined that
antiviral CTL generation in the context of provided CD80/
86-CD28 co-stimulation did not render the responder T cells
less sensitive to inhibition by FasL+ AKR.H-2b veto cells (Fig.
9). Thus, vetoing through FasL/Fas interactions appears to be
dominant over CD80/86-CD28 co-stimulation.
Another possibility is that certain DC subpopulations have
the ability to function as veto cells, but this is masked by the
majority of DC which are very stimulatory. To test whether
myeloid, lymphoid, and plasmacytoid DC subset cells each
exhibited a similar inability to veto antiviral CTL production,
flow cytometric sorting of these purified CD11c+ DC subsets
allowed them to be tested for veto capacity in CTL
restimulation cultures (Fig. 10). However, these purified
myeloid (CD8a/B220), lymphoid (CD8a+/B220), and
plasmacytoid (CD8a/B220+), DC subsets each demonstrated
an inability to inhibit the KSPWFTTL peptide-stimulated
antiviral CTL responsiveness, compared to control inhibition
mediated by unfractionated AKR.H-2b splenocytes (Fig. 10).
Thus, there was no evidence that there was a DC subpopulation
that was inherently veto-capable, but masked by other non-
veto, stimulatory DC cells.
Our results on the inability of spontaneous retrovirus-
infected DC populations to inhibit the antiviral CD8+ CTL
response, specifically by a FasL-dependent veto/AICD mech-
anism, are interesting to compare to other studies on the
negative roles DC can play in various antigen-specific T cell
responses. It has been appreciated for some time that DC,
though highly stimulatory in general, are under certain
circumstances able to serve as antigen-specific negative
regulatory cells. In particular, a number of studies have
reported that the DEC 205+ CD8a+ ‘‘lymphoid’’ DC subset
is either less stimulatory or overtly inhibitory, compared to the
DEC 205 CD8a CD11b+ ‘‘myeloid’’ DC subset. For
example, Kronin et al. (1997) have questioned whether the
CD8a+ lymphoid DC down-modulating regulatory effect on
allospecific CD4+ or CD8+ T cell proliferative responses
occurred via veto cell action specifically involving the DC
CD8 molecule. By use of both CD8/ DC donors and allele-
specific anti-CD8 blocking mAb, they concluded that DC CD8
was not required. Further, because their definition of veto
activity was restricted to only those inhibitory mechanisms that
involve functional CD8, they suggested that the observed
down-modulation by CD8+ DC was due to a non-veto cell
mechanism.
In contrast, we find no consistently substantial inhibition by
DC in our system using either unfractionated DC (Figs. 5, 6)
or, as just discussed above, isolated myeloid, lymphoid, or
plasmacytoid AKR.H-2b DC. Other differences in the two
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broader definition of veto cells, include (1) our focus on CTL
responses rather than T cell proliferation, (2) our use of
retrovirus-infected DC from AKR.H-2b mice that spontane-
ously express infectious virus and viral antigens, and (3) the
universal involvement of FasL/Fas-mediated apoptosis as the
veto cell inhibitory mechanism in the present system. Our latter
finding is to be contrasted with the allo system cited where DC
inhibition of CD4+ T cell responses was previously shown to
occur by FasL/Fas apoptosis, but inhibition of CD8+ T cell
proliferation was via the limited IL-2 production induced by
the DC APC (Kronin et al., 1996; Suss and Shortman, 1996).
Other studies have suggested a more widespread role for
DC-expressed FasL and ensuing inhibition of T cell responses
and other cells by apoptosis. Thus, functional FasL expression
has been demonstrated by other murine DC populations,
including Langerhans cells and bone-marrow-derived/myeloid
DC (Shibaki and Katz, 2001; Lu et al., 1997), and by human
DC, along with other TNF family ligands such as TRAIL and
lymphotoxin a1h2 (Fanger et al., 1999; Liu et al., 2001; Lu et
al., 2002). Similarly, DC have been engineered to express FasL
and shown to thus acquire the ability to inhibit antigen-specific
responses (Matsue et al., 1999; Min et al., 2000; O’Connell et
al., 2002). In short, it appears that some, or perhaps most, DC
populations either can function as FasL/TNF-ligand apoptosis
inducing veto cells or have the inherent capability to do so if
provided with sufficient FasL expression. These collective
results further highlight the unexpected finding in the present
system that AKR.H-2b DC, although otherwise apparently
functional, are not efficient veto cells compared to their
lymphoid subset counterparts.
Clearly, these and other questions about the detailed
mechanism of veto cell inhibition, and the differential ability
of lymphoid versus APC virus-infected cell types to inhibit,
will require further experimentation. Especially tantalizing is
the possibility that retrovirus infection and specific viral gene
expression induces FasL expression and/or otherwise con-
verts some cell types into veto cells but not other cell types.
Regardless of the mechanistic details, however, the physio-
logic importance of this veto cell system should be stressed.
The presence of functioning veto cells in several lymphoid
tissue sites throughout the AKR.H-2b mouse (Fig. 2) and our
previous inability to elicit specific antiviral CTL responsive-
ness in recipients of in vivo adoptively transferred splenic
AKR.H-2b veto cells (Rich and Green, 1995) underscore
peripheral tolerance mediated by veto cells as the likely
cause for the selective CTL non-responsiveness of AKR.H-2b
mice.
Materials and methods
Mice
Seven-week-old male C57BL/6 (B6) mice were obtained
from the National Institutes of Heath, Bethesda, MD, and the
B6.MRL-Faslpr (B6.lpr) and B6.CD80/CD86mice, from the
Jackson Laboratory, Bar Harbor, Maine. The AKR.H-2bcongenic mouse strain was maintained through breeding of
brother/sister pairs in the Animal Health Resource facility of
Dartmouth Medical School. Breeding pairs were originally
provided by Dr. David Myers (Sloan Kettering Memorial
Institute, New York, NY).
Cell lines
The ESG2, Gross virus induced and Gross cell surface
antigen (GCSA) positive; and E9K1, AKR virus induced but
GCSA; tumors are of the B6 (H-2b) strain origin. The E9K1
tumor line was always used as a negative control target; the
data showing no substantial lysis were omitted for the sake of
brevity. AKR.H-2b SL1 (SL1), a spontaneous GCSA+ tumor,
was derived from an AKR.H-2b mouse. B.GV, a Gross virus
induced GCSA+ tumor, was derived from a BALB.B (H-2b)
mouse. BALB.B-1K, a tumor line also of BALB.B origin, is
insusceptible to AKR/Gross MuLV-specific CTL. All tumor
cell lines used have previously been described in detail (Rich
and Green, 1996). Cell lines were maintained by thrice weekly
in vitro passage in RPMI 1640 (Gibco, Grand Island, NY)
supplemented with 5% fetal bovine serum, 5  105 M 2-
mercaptoethanol, l-glutamine, and antibiotics (TC media).
Polyclonal antiviral CTL generation
AKR/Gross MuLV-specific CTL were generated following
i.p. inoculation of B6 responder mice with 1–2  106 non-
syngeneic, H-2b-matched B.GVor SL1 tumor cells. 11–14 days
post-inoculation, 107 immune spleen cells were cultured in
mixed lymphocyte tumor cell cultures (MLTC) with 2  105
irradiated ESG2 tumor stimulator cells, as previously described
(Green et al., 1980).
Flt3L inoculations, collagenase D treatments and AKR.H-2b
splenic cell subset purifications
AKR.H-2b cervical, mesenteric, inguinal, femoral, and
popliteal lymph nodes were extracted, pooled, and processed
to single cell suspensions by pipetting through 70-Am nylon
cell strainers (Becton Dickinson Labware, Franklin Lakes, NJ).
AKR.H-2b bone marrow was extracted from pooled long bones
and depleted of red blood cells prior to processing to single cell
suspensions. Thymocytes, which were devoid of appreciable
numbers of red blood cells, were obtained through extraction of
thymus and processing to single cell suspensions as above.
Purification of AKR.H-2b B cells was through positive
selection with anti-CD19 MicroBeads (Miltenyi), with enrich-
ment to 95–99% as measured by flow cytometric analysis.
Alternatively, utilizing the negatively selected (CD19-negative)
cells, B cells were further depleted through selection of cells
non-adherent to dishes coated with goat anti-mouse Ig
(GAMIG) (Southern Biotec, Birmingham, AL). Following B
cell depletion, AKR.H-2b CD4+ and CD8+ T cells were further
purified by positive selection with either anti-CD4 or anti-
CD8a MicroBeads (Miltenyi), with enrichment ranging from
91–99% as measured through flow cytometric analysis.
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mice were inoculated s.c. for 9–11 consecutive days with 10 Ag
per inoculation of human recombinant Flt3L (human Chinese
hamster ovary cell derived) generously provided by Immunex,
Inc., diluted in PBS containing 1 Ag per inoculation of mouse
serum albumin (MSA) (SIGMA, St. Louis, MO). As controls for
Flt3L inoculations, AKR.H-2b mice were inoculated with 1 Ag
per inoculation of MSA in PBS and/or used as untreated mice.
For the purification of DC, cells were first enriched through
complete depletion of AKR.H-2b B cells as above. Then, DC
were obtained from B-cell-depleted preparations through
positive selection with anti-CD11c MicroBeads (Miltenyi).
Resulting DC were (93–99%) pure based on two-color flow
cytometric analysis using mAb M5/114.15.2 anti-class I-A/I-E
(or mAb AF6-120.1 anti-I-Ab) and PE-labeled mAb HL3 anti-
CD11c (each from BD-Pharmingen, San Diego, CA).
To obtain purified DC subsets, cell sorting on a FACSARIA
(BD) instrument was employed. Flt3L-stimulated splenic
CD11c+ DC were prepared as just described. By gating on the
defined PE-labeled anti-CD11c (Pharmingen) mAb total DC
population, DC subset cells were positively sorted using mAb to
anti-B220 (for plasmacytoid DC) or anti-CD8a (for lymphoid
DC). B220/CD8a double negative cells represented the
myeloid DC population. Plasmacytoid and lymphoid DC were
shown through flow cytometric analysis to be 96 and 98% pure,
respectively, whereas myeloid DC were 83% pure.
Alternatively for total DC preparations, purified AKR.H-2b
splenic ‘‘normal’’ DC were derived via collagenase D (Roche,
Indianapolis, IN) digestion of spleen, prior to purification via
GAMIG negative selection and one to two rounds of Miltenyi
bead CD11c-positive selection. Briefly, whole spleens were
treated via forceful exudation of spleen cells with 100 U/ml of
collagenase D in Hank’s buffered saline solution (HBSS)
containing calcium and magnesium. Remaining spleen sections
were cut into small pieces and treated with 400 U/ml of
collagenase D in HBSS at 37 -C for 1.5 h followed by processing
through a cell strainer (BD Falcon, Bedford, MA) to yield a
single cell suspension. Where shown and described as being
‘‘peptide-pulsed’’, DC (1 106 per well) were suspended in TC
media containing 100 ng/ml of the immunodominant Kb-
restricted CTL epitope, KSPWFTTL, for 15 min at 37 -C prior
to thrice washing, recounting of viable cells, and use in vitro as
source of antigen (Ag) in CTL restimulation cultures. Collage-
nase-derived normal DC were determined to be 92–99% pure.
CTL lytic and veto cell assays
To measure AKR.H-2b veto cell-mediated inhibition 1–2 
106 viable untreated (or MSA treated), unfractionated AKR.H-
2b splenocytes, or experimental subset cells (purified as above),
were included at the initiation of CTL-generating MLTC
cultures, as indicated. Following the standard 6 days of in
vitro restimulation, 51Cr release assays were conducted as
previously described (Rich and Green, 2002) to measure CTL
activity from these MLTC cultures. Briefly, 104 radiolabeled
tumor target cells were mixed with varying numbers of effector
cells (i.e., several E:T ratios), centrifuged, and incubated for 4h at 37 -C. Then the cells were centrifuged again, and an
aliquot of cell-free supernatant was removed for gamma
counting and data reduction. Percent specific lysis against
tumor cells is defined according to the following formula:
[(X  Y) / Z]  0%, in which X = cpm released by target cells
incubated with effector cells; Y = cpm released by target cells
incubated alone; and Z = cpm released by the freeze–thaw of
target cells (approximately 80% of total cpm incorporated).
The values for spontaneous 51Cr release by tumor target cells
were 12% except for one experiment which was 25% and
another at 30.1%. Only those experiments in which control
inhibition of tumor cell stimulated antiviral cytotoxicity,
mediated by either untreated/fractionated or MSA-treated/
fractionated AKR.H-2b splenocytes, was 70% (at E:T ratios
in the linear range of the lysis curve) and/or >5-fold (based on
comparison of the E:T ratios yielding similar levels of lysis)
were included. Using these criteria, data from <10% of
experiments performed were not included.
Real-time PCR quantification of mRNA expression
RNAwas purified from highly enriched (see above) AKR.H-
2b CD4+, CD8a+, CD19+ (B cells), and CD11c+ DC, spleno-
cytes, using Tri-Reagent (Molecular Research Center, Inc.,
Cincinnati, OH) followed by secondary purification and
DNAse-I treatment using RNeasy columns (Qiagen, Valencia,
CA) according to the manufacturer’s protocols. One microgram
of DNA-free RNA was reverse transcribed to cDNA using
Omniscript RT (Qiagen) with random hexamer priming. Real-
time PCR was performed by amplifying 0.5 ml (¨300 pg) of
cDNA with the SYBR Green PCR Core Kit (Applied Biosys-
tems, Foster City, CA) on an iCycler iQ instrument (BioRad,
Hercules, California). Amplification conditions were 95 -C for
8min, followed by 40 cycles of 94 -C for 15 s, 63 -C for 45 s, and
72 -C for 15 s. The FasL primers were forward 5V-tggtggctctg-
gttggaatggg and reverse 5V-tgggccacactcctcggctc as previously
described (Medana et al., 2001). Total cDNA input was
normalized to h-actin expression measured using the primers
forward 5V-agagggaaatcgtgcgtgac and reverse 5V-caatagtgat-
gacctggccgt. The number of PCR cycles required for SYBR
green fluorescence to cross a threshold where there was a
significant increase in change in fluorescence (Ct = threshold
cycle) was measured using iCycler iQ software. Relative FasL
RNA expression was determined using the formula Rel Exp =
2(deltadeltaCt)  1000 where deltadelta CT = (Ct FasL  Ct h-
actin in experimental sample)  (Ct FasL  Ct h-actin in a no-
template control sample.
Kb/KSPWFTTL tetramer and flow cytometric analysis
Purified KSPWFTTL synthetic peptide (Research Genetics,
Huntsville, AL) was used for the production of PE-labeled Kb/
KSPWFTTL tetramer by the National Institute of Allergy and
Infectious Disease MHC Tetramer Core Facility (Atlanta, GA).
For staining of KSPWFTTL-specific CTL, 2  105 B6
responder splenocytes were incubated at 37 -C for 15 min
with a combination of APC anti-CD8a (Caltag Laboratories,
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(pre-titrated optimal concentration determined using A610.G5
cloned CTL cells of Kb/KSPWFTTL specificity). Following
the isolation of AKR.H-2b CD4+ and CD8+ T lymphocytes and
B lymphocytes (as outlined above), FITC-labeled mAb
H129.19 anti-CD4, mAb 53-6.7 anti-CD8a, and mAb 1D3
anti-CD19 (BD-Pharmingen), respectively, were used in flow
cytometric analysis for the determination of cell purity which
ranged from 91 to 99%. Staining for cell surface FasL was
performed using three-color flow cytometric analysis. For
visualization and subsequent gating of AKR.H-2b CD4+ or
CD8+ T lymphocytes, cells were incubated in a cocktail of PE-
labeled mAb OX-7 anti-Thy1.1 antibody (BD-Pharmingen)
and FITC-labeled antibody to either CD4 or CD8, respectively.
AKR.H-2b DC staining was performed using PE-labeled anti-
CD11c and FITC-labeled anti-I-A/I-E (or anti-I-Ab) mAb.
Then AKR.H-2b CD4+ or CD8+ T lymphocytes or DC were
gated and analyzed for FasL positivity using biotinylated
MFL3 anti-FasL antibody (BD-Pharmingen), followed by
incubation in a 1:200 dilution of APC-labeled streptavidin
(Caltag). In order to determine the FasL positivity of AKR.H-
2b B lymphocytes, responder B6 B lymphocytes were removed
prior to initiation of the MLTC restimulation cultures through
GAMIG negative selection (see above). CD19+ AKR.H-2b B
cells were then gated and stained with MFL3 antibody as
above. Biotinylated hamster IgG1 (BD Pharmingen) was used
as an isotype control antibody for MFL3. Other isotype control
antibodies (all from BD Pharmingen) were used as appropriate.
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